# **UC Irvine** UC Irvine Previously Published Works

# Title

Diet-Induced Circadian Enhancer Remodeling Synchronizes Opposing Hepatic Lipid Metabolic Processes

Permalink https://escholarship.org/uc/item/9199v0kg

**Journal** Cell, 174(4)

**ISSN** 0092-8674

# **Authors**

Guan, Dongyin Xiong, Ying Borck, Patricia C <u>et al.</u>

Publication Date 2018-08-01

# DOI

10.1016/j.cell.2018.06.031

Peer reviewed



# **HHS Public Access**

Author manuscript Cell. Author manuscript; available in PMC 2019 August 09.

Published in final edited form as:

Cell. 2018 August 09; 174(4): 831-842.e12. doi:10.1016/j.cell.2018.06.031.

# Diet-induced circadian enhancer remodeling synchronizes opposing hepatic lipid metabolic processes

Dongyin Guan<sup>1,2</sup>, Ying Xiong<sup>1,2</sup>, Patricia C. Borck<sup>1,2</sup>, Cholsoon Jang<sup>4</sup>, Paschalis-Thomas Doulias<sup>5</sup>, Romeo Papazyan<sup>1,2</sup>, Bin Fang<sup>1,2,6</sup>, Chunjie Jiang<sup>1,2</sup>, Yuxiang Zhang<sup>1,2</sup>, Erika R. Briggs<sup>1,2</sup>, Wenxiang Hu<sup>1,2</sup>, David Steger<sup>1,2</sup>, Harry Ischiropoulos<sup>5</sup>, Joshua D. Rabinowitz<sup>4</sup>, and Mitchell A. Lazar<sup>1,2,3,7</sup>

<sup>1</sup>Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>2</sup>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>3</sup>Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

<sup>4</sup>Lewis-Sigler Institute for Integrative Genomics and Department of Chemistry, Princeton University, Princeton, NJ 08544, USA

<sup>5</sup>Children's Hospital of Philadelphia Research Institute and Departments of Pediatrics and Systems Pharmacology & Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

# SUMMARY

Overnutrition disrupts circadian metabolic rhythms by mechanisms that are not well understood. Here we show that diet-induced obesity (DIO) causes massive remodeling of circadian enhancer activity in mouse liver, triggering synchronous high amplitude circadian rhythms of both fatty acid (FA) synthesis and oxidation. SREBP expression was rhythmically induced by DIO, leading to circadian FA synthesis and, surprisingly, FA oxidation (FAO). DIO similarly caused a high

#### DECLARATION OF INTERESTS

M.A.L. and J.D.R. are consultants to Pfizer, Inc.

Address correspondence to Mitchell A. Lazar, M.D., Ph.D. lazar@pennmedicine.upenn.edu. <sup>6</sup>Current address: Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA

<sup>&</sup>lt;sup>7</sup>Lead Contact


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

AUTHOR CONTRIBUTIONS

D.G. and M.A.L. conceptualized the study, interpreted data and wrote the manuscript, which was revised and approved by all authors. D.G. performed GRO-seq experiments and bioinformatics analysis. Y.X. and P.C.B performed RT-qPCR experiments. P.C.B. and R.P. performed western blot experiments. D.G., Y.X. and D.S. performed H3K27ac ChIP-seq experiments. C.J. and J.D.R designed and performed FA synthesis rate studies. P.T.D. and H.I. designed and performed FAO rate studies. B.F. provide helps to GRO-seq analysis. C.J. performed motif analysis. D.G. and W.H. performed Oil red O assay. Y.X., P.C.B., D.G. and W.H. assisted with animal husbandry.

amplitude circadian rhythm of PPARa, which was also required for FAO. Provision of a pharmacological activator of PPARa abrogated the requirement of SREBP for FAO (but not FA synthesis), suggesting that SREBP indirectly controls FAO via production of endogenous PPARa ligands. The high amplitude rhythm of PPARa imparted time-of-day-dependent responsiveness to lipid-lowering drugs. Thus, acquisition of rhythmicity for non-core clock components PPARa and SREBP1 remodels metabolic gene transcription in response to overnutrition and enables a chronopharmacological approach to metabolic disorders.

## **Graphical abstract**



# INTRODUCTION

Circadian rhythmicity enables organisms to predict and adapt to daily environmental changes by impacting various physiological and behavioral processes (Bass and Lazar, 2016; Takahashi, 2017). This has a genetic basis in a molecular clock, which was first discovered in *Drosophila melanogaster* (Konopka and Benzer, 1971) and has proven to be comprised of transcription factors (TFs) whose interlocking positive and negative feedback loops maintain rhythmic transcription (Sehgal, 2017). In mammals, the core clockwork is complicated by additional negative feedback loops, and this clock mechanism exists in nearly all cells of the body (Balsalobre et al., 1998; Yoo et al., 2004).

The physiological clockwork is influenced by environmental factors that define modern societies. Circadian misalignment among night shift workers and individuals with sleep disorders is increasingly recognized as a risk factor for metabolic disorders including type 2 diabetes, cardiovascular disease, hypertension and cancer (Takahashi et al., 2008). This is in part due to a dissonance between the body's endogenous timing and the artificial bombardment with light and food at different times of day (Asher and Sassone-Corsi, 2015). The nutritive environment also impacts global transcriptional and epigenomic circadian rhythms, and recent studies have described massive changes in circadian gene expression in

diet-induced obesity (DIO) (Eckel-Mahan et al., 2013; Kohsaka et al., 2007). However, the underlying mechanisms by which the nutritive environment impacts circadian rhythmicity are not well understood.

In recent years, it has become clear that core clock TFs regulate the expression not only of each other but also of hundreds of output genes (Koike et al., 2012; Menet et al., 2014; Papazyan et al., 2016b). Although the clock mechanism is ubiquitous, the outputs are tissue-specific, as determined by tissue-specific cistromes of the core TFs (Perelis et al., 2015; Zhang et al., 2015). The cistromes include functional enhancer sites, where TF binding leads to regulation of gene transcription over large genomic distances (Levine et al., 2014). Circadian enhancer activity has been reported on a genome-wide scale (Fang et al., 2014; Koike et al., 2012; Lam et al., 2013; Perelis et al., 2015), and has been exploited to identify the TFs controlling rhythmic gene expression in different phases in a specific tissue (Fang et al., 2014). In liver, for example, the core clock repressive TF Rev-erba controls circadian gene transcription directly in its own phase, and indirectly by regulating the expression E4BP4, a non-core TF that is expressed with a circadian rhythm in a different phase (Fang et al., 2014).

Here we report that DIO leads to extensive remodeling of circadian enhancers, with new or massively enhanced circadian rhythms at enhancers linked to genes involved in both FA synthesis and oxidation. We demonstrate that DIO-selective circadian rhythmicity of the lipogenic transcription factor Sterol Regulatory Element-Binding Protein (SREBP) (Horton et al., 2002) was required not only for the induction of circadian FA synthesis but, surprisingly, for FA oxidation. DIO also led to oscillation of Peroxisome Proliferated Activated Receptor a (PPARa), a major regulator of FA oxidation (Kersten, 2014), and pharmacological activation of PPARa was able to bypass the requirement of SREBP for diet-induced FA oxidation. Moreover, lipid lowering therapy with a PPARa agonist was more efficacious when administered at the daily peak of PPARa expression. Thus, the acquisition of rhythmic expression and function of non-core clock TFs PPARa and SREBP remodels metabolic gene transcription in response to a challenging nutritive environment and enables a chronopharmacological approach to metabolic disorders.

## RESULTS

#### DIO reprograms circadian hepatic enhancers and gene transcription

To determine the transcriptional effects of a DIO (60% fat, high sucrose diet) on mouse liver, we performed Global Run-On sequencing (GRO-seq) around the clock and compared the results with those on normal chow (NC). Of 1,722 gene bodies whose transcription oscillated significantly in NC, only 278 maintained circadian rhythm in DIO livers, with over half of these remaining the same phase (Figure 1A). By contrast, 1,621 gene body transcripts were circadian in DIO livers, with 1343 being induced by the diet (Figures 1A, 1B, and Table S1A). A major advantage of GRO-seq is the simultaneous determination of enhancer activities based on eRNA transcription (Li et al., 2016), which correlates with enhancer activity (Kim et al., 2010). When all circadian eRNAs were mapped to the nearest circadian gene body transcription, the phases of each enhancer-gene pair were highly correlated (r = 0.85) (Figure S1A). A positive correlation was observed between eRNA

expression and the enhancer mark H3K27ac, although the dynamic range of GRO-seq was much greater (Figure S1B). Circadian eRNAs were identified in NC and DIO livers, and filtered for H3K27Ac enrichment relative to genomic background to more stringently identify enhancers (Figure S1C). Remarkably, DIO led to remodeling of more than two-thirds of NC circadian enhancers, with 3,461 enhancers gaining circadian activity in DIO (Figures 1C, 1D, and Table S1B) while 5642 enhancers lost circadian rhythm in the overnutritive condition. Thus, DIO globally remodels the circadian enhancer landscape.

We first mined eRNAs to uncover TFs responsible for transcripts whose circadian rhythm was lost in DIO. These eRNAs were most enriched at the phase surrounding ZT22 and enriched for the Rev-erb/RORE motif (Figure S1D). Interestingly, circadian expression of Rev-erba is modestly attenuated in livers of DIO mice (Figure S1E and S1F), which could explain some though probably not all of the lost circadian enhancer activity. We then turned our focus to circadian gene transcription that was gained in DIO mice.

#### DIO induces circadian de novo lipogenesis

Compared with NC, DIO-specific circadian gene transcription was strikingly increased at ZT10 (5 PM) (Figure 2A). The DIO-specific circadian transcripts were enriched for metabolic pathways, especially those related to nonalcoholic fatty liver disease (NAFLD), amino acid degradation, glycerophospholipid metabolism, insulin resistance, and FA metabolism (Figure 2B and Figure S2A). By contrast, analysis of the common oscillating transcripts revealed a strong enrichment for circadian rhythm pathways (Figure S2B). Core clock gene expression was quite similar between NC and DIO (Figure S2C) although DIO mice eat a higher percentage of their total caloric intake in the light (Figure S2D) as previously reported (Kohsaka et al., 2007). Consistent with its effect on nascent gene transcription as well as with prior studies (Kohsaka et al., 2007), DIO induced the levels and the rhythmicity of expression of genes mediating hepatic *de novo* lipogenesis (DNL), including *Fasn, Acaca, Acly* and *Elov15* (Figure 2C). Tracing deuterated water into newly synthesized FA to quantify the rate of hepatic FA synthesis *in vivo* demonstrated that the enhanced rhythmicity of DNL gene expression reflected physiological flux, as DIO induced the magnitude in addition to the absolute rate of DNL in the liver (Figure 2D).

#### DIO-induced circadian expression of SREBP mediates changes in DNL

Consistent with the gene transcription, DIO-induced circadian eRNAs were also enriched between ZT 7-13 as compared with NC controls (Figure 3A). Unbiased analysis revealed enrichment of several TF motifs at the sites of ZT 7-13 eRNAs, with PPAR and SREBP motifs emerging from two different algorithms (Figure S3A and S3B). The motifs for other E-box binding proteins were not enriched at these eRNA loci (Figure S3C). Consistent with this, Integrated Analysis of Motif Activity and Gene Expression (IMAGE) analysis (Madsen et al., 2017) predicted that SREBP factors contributed to the expression of eRNAs whose peak around ZT10 was synchronous with potential target gene transcription (Figure 3B). IMAGE analysis also predicted that PPARa was the likely TF at the PPAR motifs. However, we first tested the adipocyte-predominant, lipogenic transcription factor PPAR $\gamma$  (Rosen et al., 2000) which also binds to the PPARE and had been previously suggested to mediated the

DIO-induced rhythmic expression of DNL genes (Eckel-Mahan et al., 2013; Murakami et al., 2016).

Consistent with prior reports (Eckel-Mahan et al., 2013), DIO induced rhythmicity of *Ppary* mRNA expression (Figure S3D), although even in DIO liver the absolute expression of *Ppary* was extremely low relative to white adipose tissue (Figure S3E). To determine whether this low level of hepatic *Ppary* expression was required for DIO-induced DNL rhythmicity, we delivered *Cre* recombinase driven by the hepatocyte-specific human thyroxine binding globulin (AAV8-TBG-Cre) to livers of mice with floxed *Ppary* alleles to abrogate *Ppary* gene expression (Figure S3F). Deletion of *Ppary* caused no significant changes in the amplitude or rhythmicity of DNL genes (Figure S3G), indicating that *Ppary* is not required for DIO-mediated circadian changes in hepatic lipogenic gene expression.

We next turned our attention to lipogenic factors other than PPAR $\gamma$  that bind motifs enriched in the DIO-induced enhancers. The highly enriched E-box motif is bound by lipogenic factor SREBP (Kim et al., 1995; Osborne, 2000) and, indeed, DIO induced a high amplitude rhythmicity of *Srebp1* (Figure 3C). By contrast, although the expression of other DNL regulators, such as *Chrebp* and *Srebp2*, which also binds to the SREBP motif, were mildly increased in DIO, their circadian rhythmicity was not enhanced (Figure S3H). Importantly, the rhythmicity of active, nuclear SREBP1 was also induced by DIO (Figure 3D). Nuclear localization of SREBP1 is controlled by INSIG2, which prevents the proteolytic processing and nuclear localization of SREBP (Engelking et al., 2005; Yabe et al., 2002). *Insig2* gained high amplitude, circadian rhythmic expression in the livers of DIO mice in a phase opposite to the circadian increase in nuclear SREBP1 (Figure 3E). The circadian trough in INSIG2 may contribute to the peak amount and timing of nuclear SREBP1, whose feed-forward activation of SREBP1 gene expression (Amemiya-Kudo et al., 2000) likely magnifies the circadian rhythm of *Srebp1* mRNA.

To evaluate the role of SREBP1 in DIO-mediated rhythmic expression of DNL pathway, AAV8-TBG-Cre was used for hepatocyte-specific deletion of SCAP, an adaptor protein that is required for SREBP activation and stability (Hua et al., 1996). As expected, deletion of SCAP led to a dramatic reduction of *Srebp1* expression in DIO mice (Figure 3F), and this was accompanied by a marked attenuation of the rhythmic expression of DNL genes (Figure 3G) and corresponding eRNAs (Figure 3H). Importantly, the magnitude and rhythmicity of *de novo* lipogenesis were also SCAP-dependent (Figure 3I). SREBP2 and its target genes *Hmgcr* and *Mvk* were also down-regulated in SCAP deficient livers, but the expression of these genes was not circadian (Figure S3I).

#### DIO induces circadian fatty acid oxidation

In addition to DNL, the GRO-seq analysis also identified newly circadian nascent transcription of genes involved in FA oxidation (FAO). Indeed, both the absolute levels and circadian rhythmicity of *Acox1*, *Aldh3a2*, *Acaa1* and *Hadh* were dramatically induced by DIO (Figure 4A). In addition to these genes that directly contribute to FAO, DIO also induced circadian rhythmicity of the gene encoding Adipose Triglyceride Lipase (*Atgl*), which contributes to the production of ligand for the master transcriptional regulator of FAO, PPARa (Figure 4B) (Ong et al., 2011; Zechner et al., 2012). Indeed, the rate of FAO in

mouse DIO-liver homogenates was up-regulated, as previously reported in human (Zhu et al., 2011) and, importantly, increased at ZT10 relative to ZT22 (Figure 4C), suggesting that the processes of DNL and FAO were synchronized, as were their gene expression patterns. Interestingly, in white adipose tissue the same DNL and FAO genes did not acquire circadian rhythmicity in DIO, indicating that these dietary effects were liver-specific (Figure S4).

#### DIO-induced circadian expression of PPARa mediates the acquired rhythm of FAO

Given the enrichment of PPAR binding motifs in DIO-induced circadian eRNAs, we considered whether the gain of expression and rhythmicity of FAO gene expression could be due to PPARa. Indeed, DIO induced *Ppara* and magnified its circadian rhythm with peak expression at ZT10 (Figure 5A). By contrast, the circadian rhythm of  $Ppar\delta$  was not enhanced and its peak expression was at ZT22 (Figure S5A). To explore the potential function of PPARa in DIO-induced circadian transcription, we examined the expression of oscillating eRNAs with peak expression at ZT10 surrounding PPARa binding sites, and noted that these eRNAs have higher expression at ZT10 than at ZT22 in DIO, but not in NCfed mice (Figure 5B). Furthermore, in DIO, the transcription of genes predicted by IMAGE to be PPARa targets was also circadian with peak expression surrounding ZT10 (Figure 5C). The binding of PPARa at sites near FAO genes was circadian in DIO but not in NC mice (Figure 5D), and was specific since it was not observed in livers depleted of PPARa (Figure S5B). Moreover, DIO-induced circadian rhythms of FAO genes (Figure 5E) and corresponding eRNA expression (Figure S5C) were attenuated in livers lacking PPARa. Physiologically, PPARa was also necessary for the circadian rhythm and magnitude of FAO (Figure 5F).

#### SREBP1 activates FAO genes by promoting PPARa transcriptional activity

As the DIO-induced circadian rhythmicity of FAO genes was similar in phase to that of DNL genes, which were dependent upon SCAP/SREBP, we wondered how the loss of SCAP/SREBP would affect FAO. Remarkably, although SREBP1 is best known as a lipogenic TF, its depletion via *Scap* deletion led to a marked downregulation and attenuation of rhythmicity of the DIO-induced FAO genes (Figure 6A) and corresponding eRNA that were directly controlled by PPARa (Figure S6A). Moreover, loss of SCAP dramatically decreased basal FAO rate at both ZT10 and ZT22, and abrogated the rhythmicity of FAO rate (Figure 6B).

Since these observations were made after 12 weeks of the obesogenic diet, we next explored the chronology of the acquisition of circadian DNL and FAO gene expression. Interestingly, the induction of rhythmicity of *Insig2, Srebp1* and DNL genes was apparent after 2 weeks (Figure 6C). These effects were independent of changes serum insulin (Figure S6B), and were earlier than observed for genes in the FAO pathway, whose enhanced expression and rhythmicity tended to be later (Figure 6D). Although these genes were controlled by PPARa, the level and circadian rhythm of *Ppara* expression were not significantly altered in the absence of SREBPs (Figure 6E), leading us to hypothesize that SREBP was controlling the generation of an endogenous activating ligand of PPARa. In support of this, both *Atg1* and *Fasn*, whose circadian rhythm and expression were induced in DIO, have been suggested to contribute to endogenous PPARa ligand formation (Chakravarthy et al., 2005;

PPARa, there is evidence that 16:0/18:1-GPC fulfills the criteria (Chakravarthy et al., 2009), and interestingly 16:0/18:1-GPC levels were rhythmic, with higher concentration at ZT10 than ZT22, in an SREBP-dependent manner (Figure 6F). If SREBP was controlling an endogenous PPARa ligand, then treatment with an exogenous PPARa agonist should rescue the effect of Scap deletion on FAO. Indeed, WY-14,643 (WY) was able to overcome the inhibition of FAO gene expression in the mice lacking hepatic SCAP (Figure 6G). By contrast, WY treatment did not induce Fasn in the absence of SCAP (Figure S6C), consistent with direct effects of SREBP1 on DNL. These data support the hypothesis that SREBP promotes FAO by contributing to the generation of endogenous ligands for PPARa.

#### Pharmacological lipid lowering is more effective at the peak of PPARa expression

PPARa agonists are used in the clinic as a therapy for hyperlipidemia (Frick et al., 1987; Rubins et al., 1999). Most patients with this condition are obese (Schauer et al., 2017), yet current dosing strategies do not consider the circadian expression of PPARa in DIO. We therefore tested whether PPARa agonist therapy might be more efficacious at certain times of the day by using WY, whose elimination half-life is ~1 hour after gavage dosing (NTP, 2007). Indeed, a single oral gavage dose of WY caused more robust expression of FAO genes and pre-mRNAs (reflecting nascent transcription) at ZT8 (*Ppara* peak) than at ZT20 (Ppara trough) (Figure 7A). We then performed a 3-week study, providing WY to DIO mice by daily gavage either at ZT8 or ZT20 with a dose (3mg/kg) shown to not alter food intake (Karimian Azari et al., 2013), in 6-day cycles with a gap day after each cycle. Mice were euthanized at ZT10 after the third cycle, such that the time after last dose was 50 hours for mice dosed at ZT8 and 38 hours for ZT20-treated mice. Remarkably, livers of mice treated with WY at ZT8 exhibited reduced lipid accumulation compared with those dosed at ZT20 (Figure 7B). WY also reduced hepatic triglycerides more when dosed at ZT8 than at ZT20 (Figure 7C). Moreover, serum triglyceride levels, which are the main biomarker of PPARa agonist therapy, were lower when the drug was administered at ZT8 (Figure 7D). By contrast, expression of core clock genes and Srebp1 was not statistically different between treatment and control groups (Figure S7). Thus, in DIO mice, provision of pharmacological ligand at the time of peak PPARa expression causes maximal reduction of liver and serum triglycerides.

# DISCUSSION

We have demonstrated that an obesogenic diet induces widescale remodeling of circadian enhancers and gene transcription. Remarkably, rather than affecting the core clock TFs, DIO led to a marked and synchronous circadian oscillation of the anabolic TF SREBP1 and the catabolic TF PPARa, and corresponding rhythms of DNL and FAO, respectively. The two processes are linked by SREBP, which directly controls DNL and promotes the activity of PPARa.

For over 40 years, it has been appreciated that, in mice, hepatic DNL is circadian and is exacerbated by obesity (Hems et al., 1975). Yet the underlying mechanism for the metabolic perturbation remained unknown. The circadian control of DNL on normal chow is

determined in part by the nuclear receptor Rev-erba, which is a core clock component (Bugge et al., 2012; Cho et al., 2012; Preitner et al., 2002) that can also directly repress lipogenic genes in a circadian manner (Feng et al., 2011). Here we demonstrate that the increased circadian DNL in obesity is due to an acquired high amplitude circadian rhythm of lipogenic TF SREBP1. More broadly, our results demonstrate that the non-core clock TFs can be recruited as circadian regulators of metabolism.

SREBP and PPARa are also required for the circadian expression of eRNAs, which reflect the active enhancers, near some DNL and FAO genes. We also observed SREBP regulates the expression of several eRNAs, whose loci surround Fasn gene. This suggests functional redundancy amongst enhancers for regulation of target gene (Hong et al., 2008; Osterwalder et al., 2018; Soccio et al., 2011) can be modulated by single TF SREBP. Comparing DIOselective eRNAs and DIO-lost eRNAs in light phase did not reveal the motifs for TFs previously suggested to entrain feeding/fasting cycles and insulin response, such as FOXO1 (Vollmers et al., 2009). We recognize that phase-specific enrichment could be masked if the majority of binding was at promoters rather than enhancers, since GRO-seq cannot identify enhancer elements at promoter regions because promoter region transcription is typically divergent. It will be interesting to profile eRNA expression surrounding binding sites of these TFs in livers of NC and DIO mice. In sum, unbiased motif analysis in DIO-selective eRNAs led us to identify the motif sequences of SREBP and PPARa as selectively circadian in DIO and positively correlated with gene expression of SREBP1 and PPARa. Loss-offunction studies indicates these TFs are required for the circadian expression of eRNAs near genes involved in DNL and FAO pathways.

DNL and FAO are important for the orchestration of hepatic lipid metabolism under physiological conditions. In NAFLD, DNL is enhanced and thought to contribute to hepatic lipid accumulation, while increasing FAO via activation of PPARs is used in the clinic (Staels et al., 2013; Ye et al., 2001). However, emerging data suggest a beneficial effect of DNL in preventing lipotoxicity. For example, ectopic expression of nuclear SREBP1c prevents lipotoxic liver damage in HDAC3 and SCAP (SREBP cleavage-activating protein) hepatic double knockout mice (Papazyan et al., 2016a). The present study suggests that DNL has a beneficial effect by dynamically providing endogenous activators of PPARa in the lipid-overloaded liver of DIO mice. FASN has previously been shown to be required for endogenous generation of the putative PPARa ligand 16:0/18:1-GPC (Chakravarthy et al., 2009) in a diet containing no fat. Here we show that an obesogenic diet high in fat and sucrose leads to circadian production of this putative ligand in a Scap-dependent manner. We speculate that the DIO-induced synchronization of opposing hepatic lipid metabolic processes is an adaptive response to the overnutritive environment, although clearly they are not sufficiently homeostatic since fatty liver and insulin resistance develop under the same conditions. Whether this is partially protective, or ultimately maladaptive, for example by generating ROS or other toxic products, remains to be determined.

Chronotherapy refers to the principle of administering drugs at times when they are most effective and/or best tolerated to enhance effectiveness and reduce toxicity (Ohdo, 2010). There are some precedents in the field of lipid metabolism, where statins have been reported to be more effective in the evening due to the maximized cholesterol synthesis rate (Saito et

al., 1991). However, several studies have reported that dosing time does not affect statins efficiency (Izquierdo-Palomares et al., 2016; Kim et al., 2013; Martin et al., 2002; Plakogiannis et al., 2005). PPARa agonists have clinical application in the treatment of lipid disorders, but they also have side-effects including toxicity in muscle (Hodel, 2002). In light of our observation of a markedly circadian oscillation of PPARa expression on DIO, we noted increased efficacy of a short-acting PPARa agonist at ZT8 versus ZT20. These results support the chronotherapeutic notion that, due to the rhythmicity of PPARa in DIO, pharmacological lipid lowering is more effective at specific times of day. Indeed, recent studies have shown that *Ppara* expression oscillates in human liver (Anafi et al., 2017; Ueda et al., 2004), further supporting the potential role of PPARa agonists as chronotherapeutic agents.

## STAR \* METHODS

Detailed methods are provided in the online version of this paper and include the following:

#### **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
BrdU	Santa Cruz Biotechnology	Cat# sc-32323, RRID:AB_626766
H3K27ac	Abcam	Cat# ab4729, RRID:AB_2118291
PPARa	Santa Cruz Biotechnology	Cat# sc-398394
SREBP1c	Abcam	Cat# ab3259, RRID:AB_303650
RAD21	Cell Signaling Technology	Cat# 4321S, RRID:AB_1904106
Chemicals and Reagents		
TRIzol	ThermoFisher Scientific	Cat# 10296010
CircLigase ssDNA Ligase	Epicentre	Cat# CL4111K
BrUPT	Sigma	Cat# B7166
cOmplete, EDT-free Protease Inhibitor Cocktail	Roche	Cat# 11873580001
SUPERase-In RNAse Inhibitor	ThermoFisher Scientific	Cat# AM2696
Deuterium oxide	Sigma	Cat# 435767
WY 14,643	Cayman	Cat# 70730
9,10- <sup>3</sup> H-palmitoyl-CoA	PerkinElmer	Cat# NET043001MC
Low Range ssRNA Ladder	New England Biolabs	Cat# N0364S
APE 1	New England Biolabs	Cat# M0282S
TrackIt 25 bp DNA Ladder	Thermo Fisher Scientific	Cat# 10488-022
Novex TBE-Urea Gels, 10%, 10 well	Thermo Fisher Scientific	Cat# EC6875BOX
Novex TBE Gels, 10%, 12 well	Thermo Fisher Scientific	Cat# EC62752BOX
Novex TBE Running Buffer (5x)	Thermo Fisher Scientific	Cat# LC6675
ChIP DNA Clean & Concentrator- Capped column	Zymo Research	Cat# D5205

REAGENT or RESOURCE	SOURCE	IDENTIFIER		
DNA LoBind Microcentrifuge Tube	Eppendorf	Cat# 30108.051		
Exonuclease I (E. coli)	New England Biolabs	Cat# M0293L		
Novex TBE-Urea Sample Buffer (2x)	Thermo Fisher Scientific	Cat# LC6876		
Novex Hi-Density TBE Sample Buffer (5x)	Thermo Fisher Scientific	Cat# LC6678		
SuperScript III Reverse Transcriptase	Thermo Fisher Scientific	Cat# 18080-051		
Deoxynucleotide (dNTP) Solution Mix	New England Biolabs	Cat# N0447S		
SYBR Gold Nucleic Acid Gel Stain	Thermo Fisher Scientific	Cat# S11494		
Phusion Hot Start II DNA Polymerase	Thermo Fisher Scientific	Cat# F-549L		
E. coli Poly (A) Polymerase	New England Biolabs	Cat# M0276S		
UltraPure Glycogen	Thermo Fisher Scientific	Cat# 10814010		
TURBO DNA-free Kit	Thermo Fisher Scientific	Cat# AM1907		
Micro Bio-Spin P-30 Gel Columns	Bio-Rad	Cat# 732-6250		
RNA Fragmentation Reagents	Thermo Fisher Scientific	Cat# AM8740		
T4 Polynucleotide Kinase	New England Biolabs	Cat# Y904L		
SSPE (20x)	Thermo Fisher Scientific	Cat# AM9767		
NuPAGE 4-12% Bis-Tris Protein Gels, 1.0 mm, 10-well	Thermo Fisher Scientific	Cat# NP0321 BOX		
NuPAGE MOPS SDS Running Buffer (20X)	Thermo Fisher Scientific	Cat# NP0001		
NuPAGE LDS Sample Buffer (4X)	Thermo Fisher Scientific	Cat# NP0008		
HistoPrep Media	Thermo Fisher Scientific	Cat# SH75-125D		
AG 1-X8 formate resin	Bio-Rad	Cat# 1401443		
Critical Commercial Assays				
RNeasy Mini Kit	Qiagen	Cat# 74106		
High-Capacity cDNA Reverse Transcription Kit	Applied Biosystems	Cat# 4368813		
Triglyceride Assay Kit	StanBio	Cat# 2100-430		
Deposited Data				
GRO-seq in DIO	This study	GEO: GSE108878		
H3K27ac ChIP-seq	This study	GEO: GSE108878		
GRO-seq in NC	(Fang et al., 2014)	GEO: GSE59486		
H3K27ac ChIP-seq	(Koike et al., 2012)	GEO: GSE39860		
PPARa ChIP-seq	(Lee et al., 2014)	GEO: GSE61817		
Experimental Models: Organisms/Strains				
Mouse: C57BL/6J	Jackson labs	000664		
Mouse: C57BL/6J DIO	Jackson labs	380050		
Mouse: Scap floxed	Timothy Osborne	(Matsuda et al., 2001)		
Mouse: Pparyfloxed	Jackson labs	004584		

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Mouse: Ppara -/-	Jackson labs	008154
Oligonucleotides		
See Table S3 for qPCR primer list		
See Table S4 for ChIP-qPCR prime	r list	
Software and Algorithms		
Bowtie 1.1.1	(Langmead et al., 2009)	http://bowtie-bio.sourceforge.net/index.shtml
SAMtools 1.1	(Li et al., 2009)	http://samtools.sourceforge.net/
Bedtools 2.19	(Quinlan and Hall, 2010)	http://bedtools.readthedocs.org/en/latest/
edgeR	(Robinson et al., 2010)	https://bioconductor.org/
pheatmap		https://cran.r-project.org/web/packages/pheatmap/
HOMER v4.6	(Heinz et al., 2010)	http://homer.salk.edu/homer/
JTK_CYCLE	(Hughes et al., 2010)	https://github.com/mfcovington/jtk-cycle
IMAGE	(Madsen et al., 2017)	https://github.com/JesperGrud/IMAGE
R 3.1.0		www.r-project.org/
Perl v5.16		https://www.perl.org
GATHER	(Chang and Nevins, 2006)	http://changlab.uth.tmc.edu/gather/gather.py
Adobe Illustrator	Adobe	Adobe.com
Other		
AAV-TBG-GFP	UPenn Vector Core	N/A
AAV-TBG-Cre	UPenn Vector Core	N/A
Rodent Diet with 60% kcal% fat	Research Diets	Cat# D12492
Normal chow	LabDiet	Cat# 5010

#### CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and request for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Mitchell A. Lazar, M.D., Ph.D. (lazar@pennmedicine.upenn.edu)

#### EXPERIMENTAL MODEL AND SUBJECT DETAILS

**Mice**—Wild type C57BL/6J male mice and DIO C57BL/6J male mice were obtained from Jackson Labs. DIO C57BL/6J male mice were fed with 12-weeks rodent diet with 60% kcal % fat (Table S5). *Scap* floxed mice were previously described (Matsuda et al., 2001) and obtained from T.F. Osborne following backcrossing to the C57BL/6J genetic background. *Ppary* floxed mice and *Ppara*<sup>-/-</sup> mice were obtained from Jackson Labs on a C57BL/6J background (Lee et al., 2014; Wang et al., 2013). All mice were housed under a 12 hr light and 12 hr dark cycle (lights on at 7 a.m. [zeitgeber time 0, ZT0] and lights off at 7 p.m. [ZT12]). For DIO experiments, male mice were given a rodent diet with 60% kcal% fat for 12 weeks starting at 8 weeks of age. Control age-matched mice were fed normal chow. The UPenn Vector Core generated the AAV vectors (AAV-TBG-GFP for control and AAV-TBG-Cre for knockout). AAVs were intravenously injected with 1.5 x 10<sup>11</sup> genome copies (GC) per mouse at 8 weeks of age prior to the start of DIO experiments. For single WY treatment,

mice were dosed at 3mg/kg WY via oral gavage either at ZT8 or ZT20. Livers were collected 6 hr after oral gavage. For 3 weeks WY treatment, the drug application regimen was oral gavage either at ZT8 or ZT20 daily for 6 day cycles of WY with a gap day after each cycle. Mice were euthanized at ZT10 after the third cycle, such that the time after the last dose was 50 hours for mice dosed at ZT8 and 38 hr for mice dosed at ZT20. All animal care and use procedures followed the guidelines of the Institutional Animal Care and Use Committee of the University of Pennsylvania in accordance with the guidelines of the NIH.

**GRO-seq**—GRO-seq was performed using livers from DIO mice, collected every three hours throughout the day following the protocol described previously (Fang et al., 2014). Briefly, livers were first subjected to dounce homogenization in cold swelling buffer (10 mM Tris pH 7.5, 2 mM MgCl<sub>2</sub>, 3 mM CaCl<sub>2</sub>, 2 U/ml Superase-In). After centrifugation at 400 g, the nuclei were extracted using lysis buffer (swelling buffer with 10% glycerol and 1% Igepal). After washing twice with lysis buffer, the nuclei were resuspended in freezing buffer (50 mM Tris pH 8.3, 40% glycerol, 5 mM MgCl<sub>2</sub>, 0.1 mM EDTA) at a concentration of  $10 \times 10^7$  nuclei/ml.  $4 \times 10^7$  nuclei were used for each library. The nuclear run-on reaction was incubated in run-on buffer (10 mM Tris pH 8.0, 5 mM MgCl<sub>2</sub>, 1 mM DTT, 300 mM KCl, 200 U/ml Superase-In, 1% Sarkosyl, 500 mM ATP, GTP and Br-UTP, 2 mM CTP) for 7 min at 30°C. Nascent transcripts were enriched with anti-BrUTP antibodies. After 10 min RNA hydrolysis and reverse transcription, all products were used for GRO-seq library preparations in parallel to reduce batch effects.

**GRO-seq data processing**—Data processing was carried out as described previously (Fang et al., 2014). After trimming to clear low-quality base, adaptor, and poly-A tailing sequence, the GRO-seq sequencing reads were aligned to the mm9 genome using Bowtie version 1.1.1. Uniquely mapped reads were extended to 150bp in the 5' to 3' direction and used for downstream analysis.

To quantify gene transcription, GRO-seq signal in gene bodies was measured using GROseq reads mapped to the sense strand of the gene in a 10kb window (+2kb to +12kb relative to the TSS) within the Refseq annotated gene body. Smaller genes between 2kb and 12kb in length were quantified using smaller window sizes, from +2kb to the transcription end site (TES). For genes shorter than 2kb, the entire gene body was used for the quantification. The mapped reads within each gene quantification window were counted using HOMER (Heinz et al., 2010) and expressed as read per kb per ten million reads (RPKTM). Genes with transcription levels greater than 5 RPKTM were considered actively transcribed. eRNA identification and quantification in DIO were performed according to previously established protocols (Fang et al., 2014). Data quality and normalization factors are shown in Table S1C, and the Pearson correlation coefficients of whole transcriptome (gene or eRNA) suggest a high degree of consistency among all samples.

Identification of NC- and DIO-specific circadian gene transcripts and eRNAs-

To determine NC- and DIO-specific gene transcripts, the time-ordered RPKTM of actively transcribed genes was duplicated and inputted to JTK\_CYCLE (Hughes et al., 2010) as a 16-time point data set. This allowed thorough identification of oscillation patterns starting at each different time point. Oscillating transcripts were defined as those with JTK\_CYCLE p

0.01, maximum RPKTM value > 5, oscillation amplitude (peak/trough) > 1.5, and oscillation period within the range of 21 to 24 hr. Based on the p value from the output of JTK\_CYCLE, we determined circadian transcription in the NC, DIO and Both conditions. We further identified enriched pathways for DIO-specific circadian genes with phase surrounding ZT10 using GATHER (Chang and Nevins, 2006).

eRNA calling was performed as previously described (Fang et al., 2014). To determine NCand DIO-specific eRNAs, *de novo* identified eRNAs in DIO were pooled together with eRNAs in NC to prepare a master eRNA peak set. Next, to call high confidence enhancers, we overlapped the identified eRNA loci with the abundance of another enhancer mark, H3K27ac. The filter used was a requirement that the H3K27Ac signal to be 3 times higher than that of matched 2 kb control regions. eRNA peaks whose loci were enriched by these criteria for H3K27ac levels were considered to be high confidence active enhancers. eRNA level was quantified by calculating GRO-seq reads mapped within ± 500bp of the eRNA locus center using HOMER, and normalized to RPKTM. For unidirectional intergenic eRNAs, tag count was performed on the DNA strand where the eRNA peak was identified. For intragenic eRNAs, tag count was performed on the antisense strand of the coding gene as previously described (Fang et al., 2014). Then, the DIO-, NC-specific and "Both" condition circadian eRNAs were determined by JTK\_CYCLE as performed for gene body transcription, except that JTK\_CYCLE p 0.05 was used to account for the higher signal to noise inherent among short transcripts.

**Motif mining and IMAGE analysis**—To identify TFs enriched in the loci of DIOselective eRNAs with phase surrounding ZT10, eRNAs within 200 kb of DIO-selective circadian genes in phase ZT 7-13 were used for motif analysis using HOMER (Heinz et al., 2010). eRNAs within 200 kb of DIO-selective circadian genes out of phase ZT7-13 were used as background. The same setting was using for IMAGE analysis (Madsen et al., 2017). Motifs were collected from CIS-BP (Weirauch et al., 2014), HOMER (Heinz et al., 2010) and HOCOMOCO (Kulakovskiy et al., 2016). Only motifs that could be mapped to mouse transcription factors were included, and redundant motifs were removed. Motifs for each TF were clustered, merged, and trimmed using methods as previously described (Madsen et al., 2017). DIO-selective circadian eRNAs and genes with phase ZT7-13 were used to compare eRNAs and genes out of phase of ZT7-13 using IMAGE with default parameters based on enhancer activities and gene expressions. In order to show the dynamic changes in motif activity, R package "pheatmap" was used. The average GRO-seq tag counts of target genes (p value < 0.05) for a given transcription factor (PPAR $\alpha$  and SREBF) were plotted using eight phases of GRO-seq data from livers of DIO mice.

**Western Blot and Gene Expression Analysis**—For western blot, nuclear fractionation was performed to determine nSREBP1 levels in mouse livers as described previously (Papazyan et al., 2016a). Lysates were resolved in 4%-12% Bis-Tris NUPAGE gradient gels with MOPS running buffer. Proteins were transferred onto polyvinylidene difluoride membranes and blotted with indicated antibodies.

For gene expression analysis, total RNA was extracted from liver tissue using Trizol reagent followed by RNeasy Mini Kit. The RNA was reverse-transcribed using the High-Capacity

cDNA Reverse Transcription Kit and analyzed by qPCR. Gene expression was normalized to the mRNA levels of the housekeeping gene *Arbp* and the level of the gene of interest in the control samples.

**Feeding Behavior Monitoring**—Feeding behavior was studied using the BioDAQ Episodic Food Intake Monitor for mice (BioDAQ, Research Diets, Inc., New Brunswick, NJ), which allows continuous monitoring of meal patterns in undisturbed mice with minimal human interference. NC or DIO mice were habituated for one week to single housing and fed with normal chow or obesogenic diet through a food hopper in regular housing cages with environmental enrichment and bedding material. Water was provided *ad libitum* from regular water bottles. The feeding behavior were monitored continuously for three days. Data are expressed as the mean  $\pm$  SEM (n = 4-6 per group). \*p < 0.05 in Student's t-test.

*In vivo* Lipogenesis Assay—Six hours prior to liver collection (ZT8 or ZT20), mice were provided 4.5  $\mu$ l/g body weight D<sub>2</sub>O every two hours for three times. Livers were quickly dissected and snap frozen in liquid nitrogen with a pre-cooled Wollenberger clamp. Then, the frozen liver samples were ground at liquid nitrogen temperature with a Cryomill (Retsch, Newtown, PA). The resulting tissue powder was weighed (10 mg). Tissue powder was incubated with 1 mL of 0.3 M KOH in 90% methanol at 80°C for 1 hr in a 2 mL glass vial for saponificati on. Formic acid (0.1 mL) was then added for neutralization. The saponified fatty acids were extracted by adding 0.5 mL of hexane, vortexing, and transferring the top hexane layer to a new glass vial. Samples were then dried under a stream of N<sub>2</sub> and dissolved in 1 mL of isopropanol:methanol (1:1, v/v) solution for LC-MS analysis. Separation was performed by reversed-phase ion-pairing chromatography on a C8 column coupled to negative-ion mode, full-scan LC-MS at 1-Hz scan time and 100,000 resolving power (stand-alone orbitrap; Thermo Fischer Scientific). Data analysis with MAVEN software and natural isotope correction were performed as previously described (Zhang et al., 2017).

16:0/18:1-GPC measurement—Analysis of lipids were performed as described previously (Feng et al., 2018). The resulting tissue powder was weighed in an Eppendorf tube (10 mg). The tissue powder was then dissolved with 1 mL of 0.1 M HCl/MeOH (50/50). Next, 0.5 mL of chloroform was added and vortexed for 10 seconds. After centrifugation at 14,000 g and 4°C for 10 min, the bottom layer was collected with a glass syringe and transferred to a glass MS vial. Samples were then dried under a stream of N<sub>2</sub>, dissolved in 1 mL of isopropanol: methanol (1:1, v/v) solution and injected into a 1290 Infinity UHPLC system coupled to an Agilent 6550 iFunnel Q-TOF mass spectrometer. To cover both the positive charged (ESI+) and negative charged (ESI-) species, each sample was analyzed twice using the same LC gradient but with different mass spectrometer ionization modes. The LC separation was performed on an Agilent Poroshell 120 EC-C18 column ( $150 \times 2.1$  mm, 2.7 m particle size) with a flow rate of 150 L/min. Solvent A was 1 mM ammonium acetate + 0.2% acetic acid in water/methanol (90:10). Solvent B was 1 mM ammonium acetate + 0.2% acetic acid in methanol/2-propanol (2:98). The solvent gradient in volume ratios was as follows: 0–2 min, 25% B; 2–4 min, 25 to 65% B; 4–16 min, 65 to 100% B; 16–20 min, 100% B; 20–21 min, 100 to 25% B; 21–27 min, 25% B. Data obtained

by QTOF were first converted into mzXML format and then processed using MAVEN software (http://maven.princeton.edu) to obtain the signal intensity of ~200 lipid species. The data were filtered by interquartile range and normalized to the total intensity for further analysis. The peak identity of 16:0/18:1-GPC was confirmed by MS/MS.

**Quantification of β-oxidation rate**—300 μg of protein suspension was added to 1 ml of Krebs-Ringer bicarbonate buffer containing fatty acid-free bovine serum albumin (2.5 mg/ ml), 2.5 mM palmitic acid, 10mM carnitine, and 4 mCi of 9,10-<sup>3</sup>H-palmitoyl-CoA. The mixture was rocked for 2 hr in the dark at 37°C, followed by Folch-based separation of 9,10-<sup>3</sup>H-palmitoyl-CoA and <sup>3</sup>H<sub>2</sub>O. The aqueous phase was collected, and proteins were precipitated by the addition of 10% tricarboxylic acid followed by centrifugation at 8000 g for 10 min at room temperature. The remaining radioactive palmitoyl-CoA was eliminated by strong anion exchange chromatography with AG 1-X8 formate resin. The effluent containing the <sup>3</sup>H<sub>2</sub>O was collected and used for scintillation counting.

**ChIP**—ChIP assays were carried out as described previously (Zhang et al., 2015). Briefly, mouse livers were harvested, minced, and cross-linked in 1% formaldehyde for 20 min followed by quenching with 1/20 volume of 2.5 M glycine solution for 5 min and two washes with 1× PBS. Chromatin fragmentation was performed by sonication in lysis buffer (50 mM Tris-HCL at pH 8.0, 0.1% SDS, 10 mM EDTA) using a Bioruptor (Diagenode). Proteins were immunoprecipitated in ChIP buffer using anti-PPARa antibody or anti-H3K27ac overnight. Cross-linking was reversed overnight at 65°C in SDS buffer (50 mM Tris-HCL, 10 mM EDTA, 1% SDS at pH 8), and DNA was isolated using phenol/ chloroform/isoamyl alcohol. Precipitated DNA was analyzed by qPCR or high-throughput sequencing.

**ChIP-seq**—H3K27ac ChIP experiments were performed independently on liver samples from NC or DIO mice harvested at ZT10 or ZT22. DNA was amplified according to the ChIP-seq sample preparation guide provided by Illumina using adaptor oligo and primers from Illumina, enzymes from New England Biolabs, and PCR purification kit and MinElute kit from Qiagen. All ChIP-seq libraries were sequenced on Hiseq 2500 (single-end 50bp) by the Functional Genomics Core of the Penn Diabetes Research Center.

**ChIP-seq data processing**—Sequenced reads were aligned to the mouse reference genome (mm9) using Bowtie version 1.1.1 (Langmead et al., 2009) with parameters '-n 1 -m 1'. Only one uniquely aligning read per genomic position was kept for further analysis. Peak calling was performed with HOMER (Heinz et al., 2010). Data quality and ChIP efficiency are shown in the Table S1D.

**Metabolic Profiling and Histology**—For hepatic triglyceride profiling, liver powder (5 mg) was dissolved in 1 mL of 0.1 M HCl in 50:50 methanol: $H_2O$ . Then, 0.5 mL of chloroform was added to the mixture and vortexed. Samples were then centrifuged at 16,000 g for 5 min and the chloroform phase at the bottom was transferred to a glass vial as the first extract using a Hamilton syringe. 0.5 mL chloroform was added to the remaining material and the extraction was repeated to get the second extract. The combined extract was dried under a stream of N<sub>2</sub> and dissolved in 1 mL of isopropanol:methanol (1:1, v/v) solution for

LC-MS analysis. Triglyceride species were detected with a positive ion mode on a Q Exactive Plus mass spectrometer coupled to a Vanquish UHPLC System (ThermoFisher Scientific, San Jose, CA). The LC separation was achieved on an Agilent Poroshell 120 EC-C18 column (150 x 2.1 mm, 2.7  $\mu$ m particle size) at a flow rate of 150  $\mu$ L/min. The gradient was 0 min, 25% B; 2 min, 25% B; 4 min, 65% B; 16 min, 100% B; 20 min, 100% B; 21 min, 25% B; 27 min, 25% B. Solvent A is 1 mM Ammonium acetate + 0.2% acetic acid in H<sub>2</sub>O:methanol (90:10). Solvent B is 1 mM Ammonium acetate + 0.2% acetic acid in Methanol:2-propanol (2:98).

For Oil Red O staining, fixed tissues were snap frozen in HistoPrep media and sectioned. The sections were stained with 0.5% Oil Red O in propylene glycerol overnight and then in hematoxylin for 5 sec. The procedures were performed by the Penn Digestive Disease Center Morphology Core.

Serum triglyceride levels were measured using a Triglyceride Assay Kit (StanBio) following the manufacturer's protocol.

#### QUANTIFICATION AND STATISTICAL ANALYSIS

Error bars represent the SEM, and statistical significance was determined by unpaired twotailed Student t-test; a p value of 0.05 was considered significant. Statistical tests were performed using R or MS Excel.

#### DATA AND SOFTWARE AVAILABILITY

The GEO accession number for the GRO-seq and ChIP-seq data reported in this paper is GSE108878.

## **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank Daniel Cohen for his comments on the manuscript, and Yee Hoon Foong, Yong Hoon Kim, Jarrett Remsberg and other members of the Lazar lab for technical support and valuable discussions. We are grateful to Jesper Grud Skat Madsen and Susanne Mandrup for advice on using the IMAGE program. We thank the Functional Genomics Core, Radioimmunoassay/Biomarkers Core, and the Viral Vector Core of the Penn Diabetes Research Center (P30 DK19525) for next-generation sequencing and virus preparation, respectively. We also acknowledge the Penn DRC Metabolomics Core at Princeton (DK19525). This work was supported by the JPB Foundation (to M.A.L.) as well as by National Institutes of Health grants (R01-DK045586, to M.A.L.; R01-HL54926 to H.I.; R01-DK098542, to D.S. and F32DK116519 to D.G.). C.J. and W.X. was supported by American Diabetes Association Training Grant (1-17-PDF-076 to C.J. and 1-18-PDF-132 to W.X.).

#### References

- Amemiya-Kudo M, Shimano H, Yoshikawa T, Yahagi N, Hasty AH, Okazaki H, Tamura Y, Shionoiri F, Iizuka Y, Ohashi K, et al. Promoter analysis of the mouse sterol regulatory element-binding protein-1c gene. J Biol Chem. 2000; 275:31078–31085. [PubMed: 10918064]
- Anafi RC, Francey LJ, Hogenesch JB, Kim J. CYCLOPS reveals human transcriptional rhythms in health and disease. Proc Natl Acad Sci U S A. 2017; 114:5312–5317. [PubMed: 28439010]

- Asher G, Sassone-Corsi P. Time for food: the intimate interplay between nutrition, metabolism, and the circadian clock. Cell. 2015; 161:84–92. [PubMed: 25815987]
- Balsalobre A, Damiola F, Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell. 1998; 93:929–937. [PubMed: 9635423]
- Bass J, Lazar MA. Circadian time signatures of fitness and disease. Science. 2016; 354:994–999. [PubMed: 27885004]
- Bugge A, Feng D, Everett LJ, Briggs ER, Mullican SE, Wang F, Jager J, Lazar MA. Rev-erbalpha and Rev-erbbeta coordinately protect the circadian clock and normal metabolic function. Genes Dev. 2012; 26:657–667. [PubMed: 22474260]
- Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, Semenkovich CF. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell. 2009; 138:476–488. [PubMed: 19646743]
- Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 2005; 1:309–322. [PubMed: 16054078]
- Chang JT, Nevins JR. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics. 2006; 22:2926–2933. [PubMed: 17000751]
- Cho H, Zhao X, Hatori M, Yu RT, Barish GD, Lam MT, Chong LW, DiTacchio L, Atkins AR, Glass CK, et al. Regulation of circadian behaviour and metabolism by REV-ERB-alpha and REV-ERBbeta. Nature. 2012; 485:123–127. [PubMed: 22460952]
- Eckel-Mahan KL, Patel VR, de Mateo S, Orozco-Solis R, Ceglia NJ, Sahar S, Dilag-Penilla SA, Dyar KA, Baldi P, Sassone-Corsi P. Reprogramming of the circadian clock by nutritional challenge. Cell. 2013; 155:1464–1478. [PubMed: 24360271]
- Engelking LJ, Liang G, Hammer RE, Takaishi K, Kuriyama H, Evers BM, Li WP, Horton JD, Goldstein JL, Brown MS. Schoenheimer effect explained–feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. J Clin Invest. 2005; 115:2489–2498. [PubMed: 16100574]
- Fang B, Everett LJ, Jager J, Briggs E, Armour SM, Feng D, Roy A, Gerhart-Hines Z, Sun Z, Lazar MA. Circadian enhancers coordinate multiple phases of rhythmic gene transcription in vivo. Cell. 2014; 159:1140–1152. [PubMed: 25416951]
- Feng D, Liu T, Sun Z, Bugge A, Mullican SE, Alenghat T, Liu XS, Lazar MA. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science. 2011; 331:1315– 1319. [PubMed: 21393543]
- Feng S, Gan L, Yang CS, Liu AB, Lu W, Shao P, Dai Z, Sun P, Luo Z. Effects of Stigmasterol and beta-Sitosterol on Nonalcoholic Fatty Liver Disease in a Mouse Model: A Lipidomic Analysis. J Agric Food Chem. 2018; 66:3417–3425. [PubMed: 29583004]
- Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317:1237–1245. [PubMed: 3313041]
- Haemmerle G, Moustafa T, Woelkart G, Buttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med. 2011; 17:1076–1085. [PubMed: 21857651]
- Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010; 38:576–589. [PubMed: 20513432]
- Hems DA, Rath EA, Verrinder TR. Fatty acid synthesis in liver and adipose tissue of normal and genetically obese (ob/ob) mice during the 24-hour cycle. Biochem J. 1975; 150:167–173. [PubMed: 1237298]
- Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett. 2002; 128:159–168. [PubMed: 11869826]
- Hong JW, Hendrix DA, Levine MS. Shadow enhancers as a source of evolutionary novelty. Science. 2008; 321:1314. [PubMed: 18772429]

- Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109:1125–1131. [PubMed: 11994399]
- Hua X, Nohturfft A, Goldstein JL, Brown MS. Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein. Cell. 1996; 87:415–426. [PubMed: 8898195]
- Hughes ME, Hogenesch JB, Kornacker K. JTK\_CYCLE: an efficient nonparametric algorithm for detecting rhythmic components in genome-scale data sets. J Biol Rhythms. 2010; 25:372–380. [PubMed: 20876817]
- Izquierdo-Palomares JM, Fernandez-Tabera JM, Plana MN, Anino Alba A, Gomez Alvarez P, Fernandez-Esteban I, Saiz LC, Martin-Carrillo P, Pinar Lopez O. Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia. Cochrane Database Syst Rev. 2016; 11:CD009462. [PubMed: 27888640]
- Karimian Azari E, Leitner C, Jaggi T, Langhans W, Mansouri A. Possible role of intestinal fatty acid oxidation in the eating-inhibitory effect of the PPAR-alpha agonist Wy-14643 in high-fat diet fed rats. PLoS One. 2013; 8:e74869. [PubMed: 24069361]
- Kersten S. Integrated physiology and systems biology of PPARalpha. Mol Metab. 2014; 3:354–371. [PubMed: 24944896]
- Kim JB, Spotts GD, Halvorsen YD, Shih HM, Ellenberger T, Towle HC, Spiegelman BM. Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loophelix domain. Mol Cell Biol. 1995; 15:2582–2588. [PubMed: 7739539]
- Kim SH, Kim MK, Seo HS, Hyun MS, Han KR, Cho SW, Kim YK, Hoon Park S. Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial. Clin Ther. 2013; 35:1350– 1360 e1351. [PubMed: 23998970]
- Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, Harmin DA, Laptewicz M, Barbara-Haley K, Kuersten S, et al. Widespread transcription at neuronal activity-regulated enhancers. Nature. 2010; 465:182–187. [PubMed: 20393465]
- Kohsaka A, Laposky AD, Ramsey KM, Estrada C, Joshu C, Kobayashi Y, Turek FW, Bass J. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metab. 2007; 6:414–421. [PubMed: 17983587]
- Koike N, Yoo SH, Huang HC, Kumar V, Lee C, Kim TK, Takahashi JS. Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. Science. 2012; 338:349–354. [PubMed: 22936566]
- Konopka RJ, Benzer S. Clock mutants of Drosophila melanogaster. Proc Natl Acad Sci U S A. 1971; 68:2112–2116. [PubMed: 5002428]
- Kulakovskiy IV, Vorontsov IE, Yevshin IS, Soboleva AV, Kasianov AS, Ashoor H, Ba-Alawi W, Bajic VB, Medvedeva YA, Kolpakov FA, et al. HOCOMOCO: expansion and enhancement of the collection of transcription factor binding sites models. Nucleic Acids Res. 2016; 44:D116–125. [PubMed: 26586801]
- Lam MT, Cho H, Lesch HP, Gosselin D, Heinz S, Tanaka-Oishi Y, Benner C, Kaikkonen MU, Kim AS, Kosaka M, et al. Rev-Erbs repress macrophage gene expression by inhibiting enhancerdirected transcription. Nature. 2013; 498:511–515. [PubMed: 23728303]
- Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009; 10:R25. [PubMed: 19261174]
- Lee JM, Wagner M, Xiao R, Kim KH, Feng D, Lazar MA, Moore DD. Nutrient-sensing nuclear receptors coordinate autophagy. Nature. 2014; 516:112–115. [PubMed: 25383539]
- Levine M, Cattoglio C, Tjian R. Looping back to leap forward: transcription enters a new era. Cell. 2014; 157:13–25. [PubMed: 24679523]
- Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25:2078–2079. [PubMed: 19505943]
- Li W, Notani D, Rosenfeld MG. Enhancers as non-coding RNA transcription units: recent insights and future perspectives. Nat Rev Genet. 2016; 17:207–223. [PubMed: 26948815]
- Madsen JGS, Rauch A, Van Hauwaert EL, Schmidt SF, Winnefeld M, Mandrup S. Integrated analysis of motif activity and gene expression changes of transcription factors. Genome Res. 2017


- Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002; 54:472–477. [PubMed: 12445025]
- Matsuda M, Korn BS, Hammer RE, Moon YA, Komuro R, Horton JD, Goldstein JL, Brown MS, Shimomura I. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev. 2001; 15:1206–1216. [PubMed: 11358865]
- Menet JS, Pescatore S, Rosbash M. CLOCK:BMAL1 is a pioneer-like transcription factor. Genes Dev. 2014; 28:8–13. [PubMed: 24395244]
- Murakami M, Tognini P, Liu Y, Eckel-Mahan KL, Baldi P, Sassone-Corsi P. Gut microbiota directs PPARgamma-driven reprogramming of the liver circadian clock by nutritional challenge. EMBO Rep. 2016; 17:1292–1303. [PubMed: 27418314]
- NTP. National Toxicology Program (NTP) Technical Report on the Toxicity Studies of Wy-14-643. Toxicity Report Series. 2007; 62
- Ohdo S. Chronotherapeutic strategy: Rhythm monitoring, manipulation and disruption. Adv Drug Deliv Rev. 2010; 62:859–875. [PubMed: 20188774]
- Ong KT, Mashek MT, Bu SY, Greenberg AS, Mashek DG. Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology. 2011; 53:116–126. [PubMed: 20967758]
- Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem. 2000; 275:32379–32382. [PubMed: 10934219]
- Osterwalder M, Barozzi I, Tissieres V, Fukuda-Yuzawa Y, Mannion BJ, Afzal SY, Lee EA, Zhu Y, Plajzer-Frick I, Pickle CS, et al. Enhancer redundancy provides phenotypic robustness in mammalian development. Nature. 2018; 554:239–243. [PubMed: 29420474]
- Papazyan R, Sun Z, Kim YH, Titchenell PM, Hill DA, Lu W, Damle M, Wan M, Zhang Y, Briggs ER, et al. Physiological Suppression of Lipotoxic Liver Damage by Complementary Actions of HDAC3 and SCAP/SREBP. Cell Metab. 2016a; 24:863–874. [PubMed: 27866836]
- Papazyan R, Zhang Y, Lazar MA. Genetic and epigenomic mechanisms of mammalian circadian transcription. Nat Struct Mol Biol. 2016b; 23:1045–1052. [PubMed: 27922611]
- Perelis M, Marcheva B, Ramsey KM, Schipma MJ, Hutchison AL, Taguchi A, Peek CB, Hong H, Huang W, Omura C, et al. Pancreatic beta cell enhancers regulate rhythmic transcription of genes controlling insulin secretion. Science. 2015; 350:aac4250. [PubMed: 26542580]
- Plakogiannis R, Cohen H, Taft D. Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. Am J Health Syst Pharm. 2005; 62:2491–2494. [PubMed: 16303904]
- Preitner N, Damiola F, Lopez-Molina L, Zakany J, Duboule D, Albrecht U, Schibler U. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002; 110:251–260. [PubMed: 12150932]
- Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010; 26:841–842. [PubMed: 20110278]
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26:139–140. [PubMed: 19910308]
- Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev. 2000; 14:1293–1307. [PubMed: 10837022]
- Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341:410–418. [PubMed: 10438259]
- Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb. 1991; 11:816–826. [PubMed: 2065035]

- Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med. 2017; 376:641–651. [PubMed: 28199805]
- Sehgal A. Physiology Flies with Time. Cell. 2017; 171:1232–1235. [PubMed: 29195066]
- Soccio RE, Tuteja G, Everett LJ, Li Z, Lazar MA, Kaestner KH. Species-specific strategies underlying conserved functions of metabolic transcription factors. Mol Endocrinol. 2011; 25:694–706. [PubMed: 21292830]
- Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013; 58:1941–1952. [PubMed: 23703580]
- Takahashi JS. Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet. 2017; 18:164–179. [PubMed: 27990019]
- Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet. 2008; 9:764–775. [PubMed: 18802415]
- Ueda HR, Chen W, Minami Y, Honma S, Honma K, Iino M, Hashimoto S. Molecular-timetable methods for detection of body time and rhythm disorders from single-time-point genome-wide expression profiles. Proc Natl Acad Sci U S A. 2004; 101:11227–11232. [PubMed: 15273285]
- Vollmers C, Gill S, DiTacchio L, Pulivarthy SR, Le HD, Panda S. Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. Proc Natl Acad Sci U S A. 2009; 106:21453–21458. [PubMed: 19940241]
- Wang F, Mullican SE, DiSpirito JR, Peed LC, Lazar MA. Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARgamma. Proc Natl Acad Sci U S A. 2013; 110:18656–18661. [PubMed: 24167256]
- Weirauch MT, Yang A, Albu M, Cote AG, Montenegro-Montero A, Drewe P, Najafabadi HS, Lambert SA, Mann I, Cook K, et al. Determination and inference of eukaryotic transcription factor sequence specificity. Cell. 2014; 158:1431–1443. [PubMed: 25215497]
- Yabe D, Brown MS, Goldstein JL. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci U S A. 2002; 99:12753–12758. [PubMed: 12242332]
- Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferatoractivated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes. 2001; 50:411–417. [PubMed: 11272155]
- Yoo SH, Yamazaki S, Lowrey PL, Shimomura K, Ko CH, Buhr ED, Siepka SM, Hong HK, Oh WJ, Yoo OJ, et al. PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. Proc Natl Acad Sci U S A. 2004; 101:5339–5346. [PubMed: 14963227]
- Zechner R, Zimmermann R, Eichmann TO, Kohlwein SD, Haemmerle G, Lass A, Madeo F. FAT SIGNALS–lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 2012; 15:279–291. [PubMed: 22405066]
- Zhang Y, Fang B, Emmett MJ, Damle M, Sun Z, Feng D, Armour SM, Remsberg JR, Jager J, Soccio RE, et al. GENE REGULATION. Discrete functions of nuclear receptor Rev-erbalpha couple metabolism to the clock. Science. 2015; 348:1488–1492. [PubMed: 26044300]
- Zhang Z, Chen L, Liu L, Su X, Rabinowitz JD. Chemical Basis for Deuterium Labeling of Fat and NADPH. J Am Chem Soc. 2017; 139:14368–14371. [PubMed: 28911221]
- Zhu L, Baker SS, Liu W, Tao MH, Patel R, Nowak NJ, Baker RD. Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. Metabolism. 2011; 60:1001–1011. [PubMed: 21075404]

### HIGHLIGHTS


- Diet-induced obesity (DIO) globally remodels circadian enhancers in liver
- Opposing lipid pathways develop synchronous high amplitude circadian rhythms in DIO
- DIO-enhanced circadian transcription of lipid genes requires SREBP and PPARa
- Pharmacological lipid lowering is more effective at peak expression of PPARa in DIO

Overnutrition enforces circadian rhythmicity non-core clock genes SREBP and PPARa such that pharmacological lipid lowering is more effective when PPARa is highest.




#### Figure 1. DIO reprograms circadian hepatic enhancers and gene transcription

(A and C) Identification of circadian gene transcription (A) and eRNAs (C) in NC, DIO and both conditions (upper panel) and phase analysis of "both" gene transcription (A) and eRNAs (C) (lower panel). JTK\_CYCLE (Hughes et al., 2010), p 0.01 for genes and p 0.05 for eRNAs, 21 period (t) 24 hr, peak to trough ratio > 1.5. (**B and D**) Heat map of the relative transcription of DIO-specific circadian gene transcription (B) and eRNAs (D) throughout the day in NC (left) or DIO (right). The color bar indicates the scale used to show the expression of gene across eight time points, with the highest expression normalized to 1. See also Figure S1 and Table S1.



#### Figure 2. DIO induces circadian de novo lipogenesis


(A) Percentage of gene transcription at each phase that oscillated only in livers of NC or DIO mice. (B) KEGG pathways enriched in DIO-specific circadian genes with phase surrounding ZT10. (C) Relative expression of genes involved in DNL pathway in livers of NC or DIO mice was determined by RT-qPCR. Data are expressed as the mean  $\pm$  SEM (n = 4-6 per time point) and normalized to the minimal expression in NC mice of the day. Data are double-plotted for better visualization. (D) *In vivo* fatty acid synthesis rates were measured in livers of mice after oral gavage of D<sub>2</sub>O either at ZT8 or at ZT20. Data are presented as mean  $\pm$  SEM. \*p < 0.05 in Student's t-test (n = 5 mice per group). See also Figure S2.




#### Figure 3. DIO-induced circadian expression of SREBP mediates changes in DNL


(A) Percentage of eRNAs that oscillated only in livers of NC or DIO mice. (B) Heat map of motif activities generated by IMAGE (Madsen et al., 2017) based on enriched eRNAs and gene transcription with phase between ZT7-13 in eight eRNA phases (weighted p value < 0.01). Out- of-phase eRNAs and genes were used as background. (C) Relative mRNA expression of *Srebp1* in livers of NC and DIO mice. RT-qPCR data are double-plotted for better visualization (n = 4-6 per time point). (D) Nuclear form SREBP1 (n-SREBP1) protein level in livers of NC and DIO mice (n = 4-6 per time point). Antibody specificity is confirmed by liver of *Scap* knockout mice (KO). (E) Relative mRNA expression of *Insig2* in livers of NC and DIO mice. RT-qPCR data are double-plotted for better visualization (n = 4-6 per time point). (F-H) Relative mRNA expression of *Srebp1* (F), genes involved in DNL pathway (G) and eRNAs nearby indicated genes (H) in livers of control and *Scap* knockout mice under DIO. RT-qPCR data are expressed as the mean ± SEM (n = 4-6 per group). (I) *In vivo* fatty acid synthesis rates were measured in livers of mice after oral gavage of D<sub>2</sub>O either at ZT8 or at ZT20 in livers of control and *Scap* knockout DIO mice. Data are

presented as mean  $\pm$  SEM. ns: p > 0.05 and \*p < 0.05 in Student's t-test (n = 5 mice per group). See also Figure S3.






(A-B) Relative mRNA expression of genes involved in FAO pathway (A) and *Atg1* (B) in livers of NC and DIO mice (n = 4-6 per time point). Data are expressed as the mean  $\pm$  SEM and double-plotted for better visualization. (C) Rate of <sup>3</sup>H-labeled palmiate oxidation in liver homogenates. The livers were collected at ZT10 and ZT22 in NC and DIO mice. Data are presented as mean  $\pm$  SEM. \*p < 0.05 in Student's t-test. See also Figure S4.




**Figure 5. DIO-induced circadian expression of PPARa mediates the acquired rhythm of FAO** (**A**) Relative mRNA expression of *Ppara* in livers of NC and DIO mice (n = 4-6 per time point). Data are double-plotted for better visualization. (**B**) Expression changes (ZT10 vs ZT22) in livers of NC mice (blue) and DIO mice (red) for eRNAs surrounding PPARa binding sites. \*\*\*p < 0.001 in Student's t-test. (**C**) Average gene body transcription of genes predicted by IMAGE to be regulated by PPARa. Bar plot shows average GRO-seq tag counts for targeted genes. (**D**) PPARa ChIP-qPCR for *Acox1*, *Aldh3a2*, *Acaa1*, *Hadh* and *Ins* from livers in NC or DIO mice, which were collected at ZT10 or ZT22 (n = 4-5 per group). (**E**) Relative mRNA expression of *Acox1*, *Aldh3a2*, *Acaa1* and *Hadh* in livers of control or *Ppara* knockout DIO mice, which were collected at ZT10 or ZT22 (n = 3-5 per group). RT-qPCR data are presented as the mean ± SEM. *ns*: p > 0.05 and \*p < 0.05 in Student's t-test. (**F**) Rate of <sup>3</sup>H-labeled palmate oxidation liver homogenates of control and *Ppara* knockout DIO mice, which were collected at ZT10 or ZT22. Data are presented as the mean ± SEM. \*p < 0.05 and \*\*\*p < 0.001 in Student's t-test. See also Figure S5.



**Figure 6.** SREBP1 activates FAO genes by promoting PPARa transcriptional activity (A) Relative mRNA expression of FAO genes, including *Acox1*, *Aldh3a2* and *Acaa1* in livers of control or *Scap* knockout DIO mice, which were collected at ZT10 or ZT22 (n =3-5 per group). (B) Rate of <sup>3</sup>H-labeled palmate oxidation liver homogenates of control and *Scap* knockout DIO mice, which were collected at ZT10 or ZT22. (C) Relative mRNA expression of Insig2, Srebp1 and Srebp1 target genes at ZT10 or ZT22 in the livers of normal chow mice followed by 2, 4 and 12 weeks on the hypernutritive diet (n = 3-5 per group). (D) Relative mRNA expression of PPARa and its target genes at ZT10 or ZT22 in the livers of normal chow mice followed by 2, 4 and 12 weeks on the hypernutritive diet (n =3-5 per group). (E) Relative mRNA expression of *Ppara* in livers of control or *Scap* knockout DIO mice, which were collected at ZT10 or ZT22 (n = 3-5 per group). (F) Relative abundance of 16:0/18:1-GPC in livers of control or *Scap* knockout DIO mice, which were collected at ZT10 or ZT22 (n = 4 per group). (G) Relative expression of FAO genes in livers of control and *Scap* knockout DIO mice with or without receiving WY (n = 4 mice per

group). RT-qPCR data are presented as mean  $\pm$  SEM. \* p < 0.05 in Student's t-test. See also Figure S6.



**Figure 7.** Pharmacological lipid lowering is more effective at the peak of PPARa expression (A) RT-qPCR showing the effect of WY (3mg/kg) on the mature mRNA and pre-mRNA of *Acaa1* and *Aldh3a2* at ZT8 and at ZT20 (n = 4-5 mice per group). RT-qPCR data are presented as mean  $\pm$  SEM, and \*p < 0.05 in Student's t-test. (B) Representative Oil Red O staining of livers from DIO mice with oral gavage of vehicle or WY (3 mg/kg) at ZT8 or ZT20 for three weeks. Scale bar, 50 um. (C) Heatmap displays down-regulated hepatic triglycerides (TG) species upon WY treatment at ZT8 or ZT22 as detected via mass spectrometry. Scale bar (green vs. red) represents fold change for WY vs. vehicle and scale bar (yellow vs. blue) represents average ion counts of each triglycerides species in liver with vehicle at ZT8. (D) Serum triglyceride measurements in mice described in (B). Data are presented as mean  $\pm$  SEM, and \*p < 0.05 between vehicle and WY treatments at ZT8 in Student's t-test. See also Figure S7 and Table S2.